What is the revenue and EPS growth rate for CVRx year over year?

What is CVRx's latest dividend and current dividend yield?

What does CVRx do and what are its main business segments?

What factors drove the changes in CVRx's revenue and profit?

What is CVRx's gross profit margin?

What were the key takeaways from CVRx’s earnings call?

What guidance did CVRx's management provide for the next earnings period?

Did CVRx beat or miss consensus estimates last quarter?

- **Revenue Growth**: Q3 2025 revenue up 10% YoY to $14.7M, with U.S. heart failure business leading expansion.
- **Gross Margin Expansion**: 87% gross margin (vs. 83% in Q3 2024) due to higher ASPs and manufacturing efficiencies.
- **Strategic Momentum**: 250 active centers, 10 new net centers added, and 20% of top accounts achieving ≥3 implants.
- **Reimbursement Progress**: Category I CPT code finalized for 2026, reducing prior auth friction.
- **2026 Outlook**: Mid-teens revenue growth expected, with focus on new territories and expanded clinical evidence.

**【CEO Opening Remarks】**
- Q3 2025 revenue grew 10% YoY to $14.7 million, driven by U.S. heart failure business expansion and new territory activations.
- Strategic priorities: sales force transformation, targeted account expansion, and improving patient access through reimbursement and awareness.
- 250 active implanting centers in the U.S. (up from 240 in Q2), with 10 net new centers added in Q3.
- 20% of top accounts achieved ≥3 implants, with leading sites implanting >10 patients per quarter.
- Positive reimbursement trends: CMS finalized Category I CPT code (effective Jan 2026) and maintained APC 1580 payment rates.
- FDA IDE submission for expanded RCT (EF 35-50, NT-proBNP 1,600-5,000) expected to receive feedback in late Nov 2025.

**【CFO Financial Commentary】**
- U.S. revenue: $13.5M (10% YoY), Europe: $1.2M (12% YoY), with U.S. units up 6% and Europe units down 10%.
- Gross margin improved to 87% (vs. 83% in Q3 2024), driven by higher ASPs ($31K/unit) and manufacturing efficiencies.
- R&D expenses: $3.1M (+26% YoY), SG&A: $21.9M (+1% YoY), net loss: $12.9M (-1.5% YoY).
- 2025 guidance updated: revenue $55.6-56.6M (prev $55-57M), gross margin 85-86% (prev 83-84%), OpEx $98-99M (prev $96-98M).
- Q4 2025 revenue expected: $15-16M, with sequential growth of ~6%.

**【Q&A Highlights】**
- **Sales Force Productivity**: 2025 hires are contributing more than any prior quarter; 6-12 months to full productivity. 2026 territories to expand by ~3 per quarter.
- **Reimbursement Impact**: Category I code eliminates experimental denials, reducing prior auth friction. CMS may introduce Level 6 neurostimulator code in 2026 OPPS final rule.
- **Gross Margin Sustainability**: 87% margin reflects improved ASPs and cost efficiencies; expect to maintain mid-80s range.
- **RCT Trial**: 2,000-patient trial targeting expanded HF population; CMS Category B IDE coverage needed for启动. Enrollment could begin H1 2026.
- **2026 Growth**: Mid-teens revenue growth expected, driven by new territories, reimbursement improvements, and clinical evidence expansion.
- **Expense Management**: OpEx growth rate to lag top line, with focus on operating leverage.

CVRx, Inc. (CVRX) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 2025 revenue up 15% YoY to $13.6 million, driven by U.S. heart failure expansion (120+ active centers added since Q2 2024). 
- **Sales Force Progress**: 35% of territory managers hired in 2025; early hires starting to contribute, with 3-4 territories added per quarter. 
- **Reimbursement Breakthrough**: Transition to Category 1 codes in Jan 2026 will eliminate experimental denials and ensure fair physician payment (~$550). 
- **Clinical Momentum**: IDE trial design discussions with FDA for broader patient inclusion; over 100 APP-focused educational programs in 2025. 
- **Financial Outlook**: Narrowed 2025 revenue guidance to $55-57 million; Q3 revenue expected $13.7-14.7 million. 


**【CEO Summary Section】**
- **Revenue Growth**: Q2 2025 revenue of $13.6 million, up 15% YoY, driven by U.S. heart failure revenue ($12.2 million, +15% YoY) and expanded sales territories (47 U.S. territories vs. 45 in Q1). Active implanting centers increased to 240 (from 227 in Q1 and 189 in Q2 2024). 
- **Sales Force Transformation**: 35% of territory managers hired since January 2025; focus shifting from hiring to onboarding and productivity optimization. New reps are high-quality, with >50% of area sales directors having >12 months experience. 
- **Account Strategy**: Targeting Tier 1/2 accounts (high patient volume, tech adoption) while selectively adding Tier 3/4 accounts with strong clinical/admin support (e.g., satellite centers under Tier 1 flagships). 4 criteria for sustainable programs: clinical champion, admin support, multiple prescribers, community referrals. 
- **Reimbursement Progress**: 
  - CMS proposed maintaining APC 1580 ($45k outpatient payment) and solicited comments on Level 6 code. 
  - Transition to Category 1 CPT codes in Jan 2026 will eliminate experimental denials, improve prior auth predictability, and ensure fair physician payment (~$550 national avg). 
  - 2024-2025 reimbursement improvements: higher-paying MSDRG for inpatient procedures, Category 1 codes, and APC 1580 retention. 
- **Clinical Evidence**: 
  - FDA discussions on IDE trial design for ejection fraction up to 50% and NT-proBNP up to 5,000. 
  - Investigator-sponsored research and real-world data to support adoption. 
  - Over 100 APP-focused educational programs in 2025, driving community-based awareness. 

**【CFO Financial Commentary】**
- **Q2 Financials**: 
  - Net loss: $14.7 million (-$0.57/share) vs. $14 million (-$0.65/share) YoY. 
  - Gross margin: 84% (flat YoY). 
  - SG&A: $23.4 million (+11% YoY) due to hiring, travel, and stock-based comp. 
  - R&D: $2.5 million (-11% YoY) from lower comp expenses. 
  - Cash: $95 million (down $8 million QoQ). 
- **Guidance Update**: 
  - Full year 2025 revenue: $55-57 million (narrowed from prior $54-58 million). 
  - Q3 2025 revenue: $13.7-14.7 million. 
  - Operating expenses: $96-98 million (vs. prior $95-100 million). 
  - Gross margin: 83-84% (flat). 
- **Key Drivers**: 
  - 3 territories added in Q2 (45→47), aiming for 3-4 per quarter. 
  - Productivity ramp of 2025 hires (387 implants Q2 vs. 339 Q2 2024). 

**【Q&A Key Highlights】**
- **Sales Force Ramp**: 
  - 6-12 month ramp time for new reps; early 2025 hires starting to contribute. 
  - Q2 added 2 territories (45→47); targeting 3-4 per quarter. 
  - Guidance midpoint assumes moderate productivity; top end assumes faster ramp. 
- **Reimbursement Impact**: 
  - Category 1 codes will reduce denials (currently 100% with Category III). 
  - Physician payment predictability and prior auth speed will improve. 
- **Account Strategy**: 
  - 70%+ of Q2 adds were Tier 1/2; utilization higher in these accounts. 
  - Tier 3/4 adds require clinical/admin champions (e.g., satellite centers). 
- **Clinical Trial**: 
  - Seeking CMS coverage for trial procedures; trial design discussions ongoing. 


CVRx, Inc. (CVRX) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: 15% YoY to $12.3M, despite Q1 seasonality and sales force disruption.
- **Sales Transition**: 25% of territory managers hired in Q1; 50% of team under 15 months tenure.
- **Clinical Impact**: 85% reduction in HF hospitalizations drives physician and payer engagement.
- **Guidance Update**: 2025 revenue $55M-$58M, with Q2 targeting $13M-$14M recovery.
- **Future Catalysts**: CMS reimbursement clarity, pragmatic RCT launch, and expanded clinical evidence.

**【CEO Opening Remarks】**
- Q1 2025 revenue: $12.3M (15% YoY growth), driven by U.S. heart failure business expansion and new sales territories.
- Key challenges: 
  1. Sales force realignment (25% of territory managers hired between Dec 2024 and Mar 2025) caused productivity disruptions, especially in 'dabbler' accounts reliant on relationships.
  2. Seasonality: Q1 typically lowest quarter, with patients delaying procedures due to insurance deductibles.
- Strategic priorities: 
  - Build world-class sales team with therapy development expertise.
  - Target high-potential centers with large HF patient volumes and track records of adopting novel therapies.
  - Address adoption barriers through reimbursement advocacy, physician education, and clinical evidence.

**【CFO Financial Review】**
- Gross margin: 84% (Q1 2025) vs. 85% (Q1 2024), stable despite lower revenue.
- Operating expenses: $21.2M (Q1 2025) vs. $28.3M (Q1 2024), down 25% due to reduced stock-based compensation.
- Updated 2025 guidance: 
  - Total revenue: $55M-$58M (vs. prior $53M-$56M)
  - Gross margin: 83%-84%
  - Operating expenses: $95M-$98M
- Q2 2025 outlook: $13M-$14M revenue, with expectations for gradual improvement in sales productivity.

**【Q&A Highlights】**
1. **Sales Force Transition Impact**: 
   - 50% of territory managers hired in last 15 months; 25% of hires made in Q1 2025.
   - Dabbler accounts saw 50% lower utilization vs. stable accounts, but no complete abandonments.
   - New comp plan aligns incentives with program-focused selling, driving positive behavior.
2. **Clinical Evidence Momentum**: 
   - Real-world data shows 85% reduction in HF hospitalizations.
   - Planning pragmatic RCT (1,000-2,000 patients, 100-150 centers) to expand addressable market; CMS coverage pending.
3. **Reimbursement Progress**: 
   - Proposed Level 6 Neurostimulator APC under review; expect July 2025 rule release.
   - Transitioning to Category I code in Jan 2026, with potential $45K outpatient reimbursement.


CVRx (CVRX)-8 May 25-2025 Q1 Earnings call transcript

- **Revenue Surge**: Q4 2024 U.S. Heart Failure revenue up 41% to $14.3 million, driven by 48 territories and 223 implanting centers.
- **Reimbursement Breakthrough**: CMS updates and Category 1 CPT codes for 2026 eliminate prior authorization barriers, enabling broader patient access.
- **2025 Outlook**: Guided for $63–$65 million revenue with 83–84% gross margin, positioning for sustainable growth.
- **Clinical Validation**: Long-term data shows five-fold hospitalization reduction, aligning with Phase II results and supporting Barostim as standard care.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue reached $15.3 million in Q4 2024, up 36% YoY, with U.S. Heart Failure revenue growing 41% to $14.3 million.
- **Market Expansion**: Expanded to 48 U.S. sales territories, ending the year with 223 active implanting centers (vs. 178 in 2023).
- **Patient Access**: Secured CMS reimbursement updates (APC 1580 for outpatient, DRG 276 for inpatient) and transitioned Barostim to Category 1 CPT codes for 2026, eliminating prior authorization barriers.
- **Clinical Evidence**: Published long-term data showing a five-fold reduction in hospitalizations 1 year post-implant, aligning with pre-COVID Phase II results.

**【CFO Financial Commentary】**
- **Q4 2024 Financials**: 
  - Gross profit: $12.8 million (83% margin)
  - R&D expenses: $2.8 million (+25% YoY)
  - SG&A expenses: $20.2 million (+19% YoY)
  - Net loss: $10.7 million (-$0.43 per share)
- **2025 Guidance**: 
  - Total revenue: $63–$65 million
  - Gross margin: 83–84%
  - Operating expenses: $100–$104 million
- **Cash Position**: $105.9 million as of December 31, 2024, with $12.8 million raised via AT-the-market offering.

**【Key Market Dynamics】**
- **U.S. Growth**: 457 revenue units in Q4 2024 (vs. 330 in 2023), driven by new accounts and awareness.
- **Europe Challenges**: European revenue declined to $1 million (from $1.1 million in Q4 2023), with 41 units sold (vs. 52 in 2023), reflecting reduced sales territories.
- **Cost Management**: Despite higher R&D and SG&A, maintained gross margin stability through disciplined spending.


CVRX

CVRX fundamentals

Earnings Call

You can ask Aime